Text Size: AAA

Our Partnerships

Through a history of successful collaborations, Santen has built global alliances with venture businesses, universities, research centers, and other pharmaceutical companies. Each partnership continues to bring us closer toward our mission in meeting the needs of ophthalmic patients worldwide.

Current collaborations


Merck & Co., Inc.
Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology.

Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology.


Clearside Biomedical, Inc.
Santen enters into financing and research collaboration agreements with Clearside Biomedical, Inc. for posterior
ocular disease.


Novagali Pharma S.A.
Santen acquires Novagali Pharma S.A.

Ube Industries, Ltd.
Santen collaborates with Ube Industries, Ltd. to license and develop an EP2 agonist for the treatment of ocular hypertension, including glaucoma.


MacuSight, Inc. Santen acquires worldwide rights from MacuSight, Inc. for the development and commercialization of sirolimus for the treatment of ocular diseases and conditions.

Clinical Data, Inc. Santen obtains a worldwide license to the adenosine A2A agonist compound for the development and commercialization of treatments for certain ophthalmic diseases, including glaucoma.


Merck & Co., Inc. Santen licenses the rights to tafluprost to Merck for North America, South America, Africa, and Western Europe (excluding Germany).

Bausch & Lomb Inc. Santen licenses development, manufacturing, and marketing rights of its hydrophobic acrylic lens material to Bausch & Lomb for all geographic regions, except Japan.

Other collaborations: Inspire Pharmaceuticals, Inc., Asahi Glass Co., Daiichi Sankyo, Inc., Oakwood Laboratories, LLC, and VISTAKON® Pharmaceuticals, LLC.

Learn about the benefits of partnering with Santen

Thank you for visiting Santen USA

Click continue to be redirected to Santen Worldwide at www.santen.com